SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/55042"
 

Search: onr:"swepub:oai:gup.ub.gu.se/55042" > Improved leukemia-f...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Brune, Mats,1950 (author)

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

  • Article/chapterEnglish2006

Publisher, publication year, extent ...

  • American Society of Hematology,2006

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/55042
  • https://gup.ub.gu.se/publication/55042URI
  • https://doi.org/10.1182/blood-2005-10-4073DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-24933URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The primary objective of this phase 3 study was to determine whether postconsolidation immunotherapy with interleukin-2 (IL-2) and histamine dihydrochloride (HDC) improved the leukemia-free survival (LFS) of adult patients with acute myeloid leukemia (AML) in complete remission (CR). Three hundred twenty patients with AML (median age, 57 years; range, 18-84 years) were stratified by CR1 or subsequent CR (CR > 1) and randomly assigned to treatment with HDC/IL-2 or no treatment (control). Treatment comprised 10 21-day cycles with IL-2 (16 400 U/kg) plus HDC (0.5 mg); both compounds were administered by subcutaneous injection twice daily. Study arms were balanced for age, sex, previous treatment, leukemic karyotypes, time from CR to inclusion, and frequency of secondary leukemia. Three years after enrollment of the last patient, treatment with HDC/IL-2 was found to improve LFS over control in the study population (CR1 + CR > 1, n = 320; P < .01, log-rank test). For patients in CR1 (n = 261), treatment significantly improved LFS (P = .01) with 3-year LFS estimates of 40% (HDC/IL-2) compared with 26% (control). Side effects were typically mild to moderate. These results indicate that HDC/IL-2 treatment offers an efficacious and tolerable treatment for patients with AML in remission.

Subject headings and genre

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Aged
  • 80 and over
  • Disease-Free Survival
  • Female
  • Histamine/adverse effects/ therapeutic use
  • Humans
  • Immunotherapy
  • Interleukin-2/adverse effects/ therapeutic use
  • Leukemia
  • Myeloid/ therapy
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Recurrence
  • Remission Induction
  • Survival Rate
  • Treatment Outcome
  • MEDICINE

Added entries (persons, corporate bodies, meetings, titles ...)

  • Castaigne, Sylvie (author)
  • Catalano, John (author)
  • Gehlsen, Kurt (author)
  • Ho, Anthony D (author)
  • Hofmann, Wolf-Karsten (author)
  • Hogge, Donna E (author)
  • Nilsson, Bo (author)
  • Or, Reuven (author)
  • Romero, Ana,1975 (author)
  • Rowe, Jacob M (author)
  • Simonsson, BengtUppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar(Swepub:uu)bengtss (author)
  • Spearing, Ruth (author)
  • Stadtmauer, Edward A (author)
  • Szer, Jeff (author)
  • Wallhult, Elisabeth (author)
  • Hellstrand, Kristoffer,1956Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine(Swepub:gu)xhellk (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Blood: American Society of Hematology108:1, s. 88-960006-49711528-0020

Internet link

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view